**Core tip:** Long-term hydroxyurea (HU) therapy is a rare cause of cutaneous squamous cell carcinoma (cSCC). To our knowledge, fewer than 20 cases of HU-related cSCC have been reported. Recognizing patterns of HU-associated cSCC is important for surgeons and dermatologists. Moreover, early diagnosis and evaluation are critical for determining optimal treatment regimens. We review the reported cases of cSCC and discuss the pathogenic mechanisms.

INTRODUCTION
============

Hydroxyurea (HU) is a non-alkylating antineoplastic agent first synthesized in 1869 by Dressler and Stein. It is currently used to treat leukemia, sickle cell anemia, psoriasis, and chronic myeloproliferative disorders\[[@B1]\]. Following a large-scale drug screen, it has also been used as an anti-tumor agent for the management of head and neck cancers, malignant melanoma, and brain tumors. Moreover, HU is listed as an "essential medicine" by the World Health Organization\[[@B2]\].

HU is a well-established inhibitor of DNA synthesis. It is mainly active in the S-phase of the cell cycle by suppressing ribonucleoside reductase, which plays a vital role in catalyzing the synthesis of deoxyribonucleotides from ribonucleotides\[[@B1]\]. Inactivation of ribonucleoside reductase can slow the movement of DNA polymerase at replication forks and decreases deoxyribonucleotide triphosphate levels\[[@B3]\]. Hence, HU depletes intracellular deoxynucleotide pools, which leads to impairment of DNA synthesis and repair.

There have been numerous reports of cutaneous complications during long-term maintenance therapy with HU. Common cutaneous side effects include hyperpigmentation, xerosis, alopecia, atrophy of the skin, nail changes, facial and acral erythema, palmar or plantar keratoderma, and leg ulcers\[[@B4]\]. However, to date, fewer than 20 cases of HU-related cutaneous squamous cell carcinoma (cSCC) have been reported. Early diagnosis and evaluation are critical for determining optimal treatment regimens. Herein, we describe an additional case of cSCC associated with long-term HU therapy.

CASE PRESENTATION
=================

Chief complaints
----------------

A 67-year-old Asian woman with a history of primary myelofibrosis presented with a painful non-healing chronic ulcer on her left ankle of 2 years duration.

History of present illness
--------------------------

The patient had primary myelofibrosis for 20 years and was initially treated with HU at a dose of 1 g/d.

History of past illness
-----------------------

Appendectomy was performed 10 years ago.

Personal and family history
---------------------------

The patient had no significant family history.

Physical examination upon admission
-----------------------------------

There was extensive photodamage and atrophy on the dorsal hands. The lesions on the hands consisted of multiple scabs, the largest scab on the right hand measured 1 cm × 2 cm (Figure [1](#F1){ref-type="fig"}). The irregularly shaped ulcer on the left ankle was 9 cm × 7 cm in size with an ill-defined margin (Figure [2](#F2){ref-type="fig"}).

![Skin lesions on both hands.](WJCC-7-4091-g001){#F1}

![Skin lesions on left ankle.](WJCC-7-4091-g002){#F2}

Laboratory diagnosis
--------------------

Laboratory investigations showed that the patient had marked leukocytosis (84.5 × 10^9^/L), a raised neutrophil count (60.8 × 10^9^/L) and platelet count (488 × 10^9^/L), and a low erythrocyte count (2.1 × 10^12^/L).

FINAL DIAGNOSIS
===============

A pathological examination of the surgical specimen revealed a well-differentiated squamous cell carcinoma with evidence of abundant cytoplasmic keratin pearls (Figure [3](#F3){ref-type="fig"}).

![Pathologic findings indicating pure, well-differentiated squamous cell carcinoma with evidence of abundant cytoplasmic keratin pearls. Hematoxylin-eosin staining, original magnification × 400.](WJCC-7-4091-g003){#F3}

TREATMENT
=========

Although surgeons considered performing resection of cSCC on her left foot and coverage with skin grafts, the operation was deemed too risky due to the high likelihood of failure and incomplete excision. Thus, the patient underwent a successful below-the-knee amputation followed by preventive right groin nodal dissection.

OUTCOME AND FOLLOW-UP
=====================

The postoperative course was uneventful with no recurrence after 12 mo of follow-up. Dermatologic changes on both hands secondary to HU therapy were extensively treated.

DISCUSSION
==========

Long-term HU therapy is a rare cause of cSCC. In total, only 18 cases, including our patient, have been reported in the literature (Table [1](#T1){ref-type="table"}). Disdier et al\[[@B5]\] first reported a patient with cSCC after HU treatment in 1991. In these reports, four primary diseases (primary myelofibrosis, polycythemia vera, essential thrombocythemia, and chronic myelocytic leukemia) and a wide age range (from 45 to 81 years) were presented. There was no significant sex difference in these cases (10 of 18 cases were men). Lesions were commonly located on the scalp, face, and extremities. Most patients had no history of precursor lesions or skin cancers, which rendered HU as the most likely culprit. Patients with HU-related cSCC typically showed symptoms after a latency period of approximately 2 to 13 years. HU treatment withdrawal, Mohs surgery, multiple debridements, and ablation were usually necessary to heal leg ulcers, but in five cases, the above therapies did not result in wound closure. It is suggested that the skin toxicity of HU is a long-term cumulative process and will persist after drug withdrawal, which could be defined as late toxicity. However, the mechanisms underlying the occurrence of HU-related cSCC are mostly unknown, but two pathogenic mechanisms have been proposed to explain this association.

###### 

Hydroxyurea-related cutaneous squamous cell carcinoma

  **Ref**.                          **Year**   **Age**   **Sex**   **Primary disease**   **HU dose**    **Latentpe-riod**   **Pathological distribution**   **Treatment**                                                     **Prognosis**
  --------------------------------- ---------- --------- --------- --------------------- -------------- ------------------- ------------------------------- ----------------------------------------------------------------- -----------------------------------------------------------------
  Saraceno et al\[[@B11]\]          2008       81        Male      PMF                   1 g/d          6 mo                Face and extremity              Imiquimod cream 5% HU was not discontinued                        CR of cSCC new skin lesions
  Wen et al\[[@B12]\]               2014       55        Female    PMF                   1 g/d          8 yr                Extremity                       Imiquimod cream 5% Surgical excision and discontinuation of HU    /
  Stone et al\[[@B9]\]              2012       62        Female    PV                    1 g/d          10 yr               Left heel                       Surgical excision and discontinuation of HU                       Complete healing of the wound after multidisciplinary treatment
  García-Martínez et al\[[@B13]\]   2012       67        Male      PV                    2 g/d          12 yr               Beside the right ear            Surgical excision and discontinuation of HU                       CR of cSCC
  Hoff et al\[[@B14]\]              2009       68        Female    PV                    /              8 yr                Lower legs                      Surgical excision and discontinuation of HU                       CR of cSCC
  Best et al\[[@B15]\]              1998       59        Female    ET                    /              8 yr                face and right hand             Surgical excision and discontinuation of HU                       Improvement after HU discontinuation
  Zaccaria et al\[[@B16]\]          2006       73        Male      ET                    1 g/d          12 yr               face                            Surgical excision and discontinuation of HU, Busulfan 8 mg/d      CR of cSCC
  Schleußinger et al\[[@B17]\]      2011       80        Female    ET                    0.75 g/d       13 yr               face                            Surgical excision                                                 /
  Disdier et al\[[@B5]\]            1991       65        Male      CML                   1 g/d          2 yr                face, scalp and both hands      Surgical excision and discontinuation of HU, radiotherapy         Continual progress
  Best et al\[[@B15]\]              1998       50        Female    CML                   2.5 g/d        5 yr                face and both hands             Surgical excision and discontinuation of HU                       New skin lesions; Died
  Stasi et al\[[@B18]\]             1992       70        Male      CML                   5.5 g/d        4 yr                face, both hands and elbows     Imiquimod cream 5%; Surgical excision and discontinuation of HU   CR of cSCC; New skin lesions
  Papi et al\[[@B19]\]              1993       70        Male      CML                   1 g/d          3 yr                Face                            Surgical excision and discontinuation of HU                       Continual progress
  Angeli-Besson et al\[[@B20]\]     1995       67        Male      CML                   1 g/d          4 yr                Scalp                           Localized electron beam therapy                                   Died
  Aste et al\[[@B21]\]              2001       60        Male      CML                   0.05-0.1 g/d   /                   Face, scalp and back of hands   Surgical excision and discontinuation of HU                       Continual progress
  Pamuk et al\[[@B22]\]             2003       73        Male      CML                   10 g/wk        3 yr                Left ear                        Surgical excision and discontinuation of HU, radiotherapy         Died
  Hao et al\[[@B23]\]               2013       45        Male      CML                   0.4-0.8 g/d    11 yr               Both hands                      Surgical excision and discontinuation of HU                       Continual progress
  Wang et al\[[@B24]\]              2013       66        Female    CML                   2-2.5 g/d      5 yr                Left hand                       Radiation treatment and discontinuation of HU                     PR of cSCC

HU: Hydroxyurea; PMF: Primary myelofibrosis; PV: Polycythemia vera; ET: Essential thrombocythemia; CML: Chronic myelocytic leukemia; CR: Complete remission; PR: Partial response; cSCC: Cutaneous squamous cell carcinoma.

Ultraviolet (UV) irradiation is most likely the primary factor leading to the development of cSCC. *In vitro*, HU inhibits natural DNA repair in UV-irradiated human skin fibroblasts and directly induces chromosome damage, which further interferes with cell replication in the basal layer of the epidermis\[[@B6],[@B7]\]. *In vivo*, HU transforms free radical nitrogen oxides that may produce high oxidative stress in patients' epithelial tissues and cooperates with UV in DNA damage, peroxidation of membrane lipids, and signal transduction pathway changes\[[@B8]\]. The synergistic effect of HU and UV radiation provides an ideal environment for the formation of cSCC. In addition, HU can markedly elevate p53 levels in basal layer keratinocytes, which increases the risk of skin cancers\[[@B9]\]. This pathogenic mechanism could explain the occurrence of cSCC in photoexposed skin.

A chronic wound environment characterized by prolonged inflammation undoubtedly plays another critical role in HU-associated cSCC\[[@B9]\]. Lower limb ulceration is a significant adverse reaction caused by long-term administration of HU. Several pathogenetic hypotheses (DNA inhibition theory, tarombokinesis, and microcirculation rheology theory) could explain the formation of lower limb ulcers. It is well-known that chronic skin damage, including ulcers, burn sites, and scars, is associated with an increased incidence of skin cancer\[[@B10]\]. In addition to the case reported here, 11 articles refer to the presence of cSCC on extremities, which are different from the light exposure area. Hence, chronic inflammation may be another main cause of cSCC in these patients.

CONCLUSION
==========

Taken together, these findings indicate that long-term HU administration can lead to the development of cSCC, probably through synergistic effects with UV or chronic inflammation. Hence, patients should be informed of the potential cutaneous toxicities of HU treatment in advance. Closer dermatologic follow-up is advisable, particularly in patients with continuous HU therapy and a long history of sun exposure. Moreover, regular protection against UV rays should be emphasized. When cSCC is identified, HU treatment withdrawal is necessary, and we recommend prompt replacement therapy as required. The skin toxicity of HU is considered late toxicity, and patients should be monitored for many years after HU discontinuation.
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